Nautilus Biotechnology has published research in Nature Methods demonstrating its ability to quantify tau protein variants at unprecedented scale. The study used the company's Iterative Mapping technology to identify 130 tau proteoform groups, including those present at just 0.1% of samples. The research revealed that disease-associated modifications accumulate on tau proteins in ordered, non-random sequences. This insight could enable development of new diagnostics and therapeutics for Alzheimer's disease and related conditions. Nautilus is now applying the same approach to α-synuclein in Parkinson's disease and AKT1, its first oncology proteoform assay. The AKT1 assay is expected to enter early access in late 2026. The Seattle-based company targets roughly 20 proteoform assays by mid-2028. The Nautilus Tau Proteoforms Assay is currently available through its Early Access Programme.

Nautilus Biotechnology, a company developing a single-molecule proteome analysis platform, reported a net loss of $14.7 million for the first quarter of 2026, compared to a $16.6 million loss in the corresponding period last year. Operating expenses decreased 14% year-over-year to $16.1 million, driven by lower salary, benefits, stock-based compensation and facilities costs. The company held $143.4 million in cash, cash equivalents and investments as of 31 March 2026. During the quarter, Nautilus initiated its Iterative Mapping Early Access Programme with Baylor College of Medicine and appointed Amber Faust, a proteomics veteran from Olink Proteomics and SomaLogic, as Vice President of Global Sales. The company is developing its Voyager Platform ahead of commercial launch.

Nautilus Biotechnology has announced Baylor College of Medicine as the first customer of its Iterative Mapping Early Access Program for the Voyager Platform. Through an NIH U01-funded study, Baylor will use Nautilus' single-molecule proteomics technology to develop a computational multi-omics toolkit for cancer research. The project, led by Professors Bing Zhang and Yongchao Dou, aims to identify aberrant protein isoforms that contribute to tumour growth, metastasis, immune evasion and therapeutic resistance. Researchers will combine computational approaches with full-length, isoform-resolved proteomic measurements from the Nautilus Voyager Platform to enable direct comparison of transcriptional and proteomic changes at unprecedented resolution. The collaboration pairs Baylor's multi-omics expertise with Nautilus' validated tau proteoforms assay to advance high-resolution cancer isoform analysis.